AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24528939 — intervention group
Group type: COMPARATOR
Intervention: HPMC diet (moderate carbohydrate, 182 g/d)
Number of subjects: 12
Study 22172502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero-derived vaccine
Number of subjects: 10460
Study 22172502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10460
Study 22172502 — intervention group
Group type: COMPARATOR
Intervention: Licensed egg-derived vaccine
Number of subjects: 10460
Study 20048236 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and infancy nurse home visitation
Number of subjects: 310
Study 16896735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year strength training program for plantar-flexion (PF) muscles
Number of subjects: 23
Study 16268973 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day and then 600 mg/day
Number of subjects: 40
Study 16268973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12383542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback
Number of subjects: 94
Study 12383542 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training without biofeedback
Number of subjects: 94
Study 10402403 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-FSH (Gonal-F, Serono) at a fixed dose of 150 IU/day for 3 days
Number of subjects: 32
Study 10402403 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-FSH (150 IU/daily) continued until follicles were 10 mm in diameter, aspiration performed 72 h later
Number of subjects: 32
Study 10402403 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 32
Study 7554064 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g/day cooked Brussels sprouts
Number of subjects: 10
Study 7554064 — intervention group
Group type: COMPARATOR
Intervention: Glucosinolates-free diet (control)
Number of subjects: 10
Study 2376838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 100
Study 2376838 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic training
Number of subjects: 100
Study 2376838 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 100
Study 547122 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (20 microgram/kg i.v.) with methylscopolamine (6 microgram/kg i.v.)
Number of subjects: 6
Study 547122 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (6 microgram/kg i.v.)
Number of subjects: 6
Study 547122 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 547122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of scopolamine and physostigmine
Number of subjects: 6
Study 29465293 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Program (moderate intensity, 60 min/session, 3 sessions/week for 12 weeks)
Number of subjects: 75
Study 29465293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PA program, continued routine lifestyle)
Number of subjects: 75
Study 28093928 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation therapy
Number of subjects: 21
Study 28093928 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 21
Study 26346300 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg daily and doxycycline 100 mg daily
Number of subjects: 292
Study 26346300 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg daily
Number of subjects: 292
Study 26346300 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 292
Study 23628835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 100
Study 23628835 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 100
Study 21482570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg administered intravenously every 12 h for 5-7 days
Number of subjects: 1228
Study 21482570 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g administered intravenously every 24 h for 5-7 days
Number of subjects: 1228
Study 19346992 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 KKW exercise
Number of subjects: 401
Study 19346992 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 KKW exercise
Number of subjects: 401
Study 19346992 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 KKW exercise
Number of subjects: 401
Study 19346992 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (control)
Number of subjects: 401
Study 16435344 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) with approximately 3,800 total shock waves, total energy delivery of 1,300 mJ/mm(2) in a single session
Number of subjects: 114
Study 16435344 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 114
Study 16435344 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 114
Study 14755147 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine 2 g/24 h by continuous intravenous infusion
Number of subjects: 107
Study 14755147 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 30 mg every 6 h as a bolus intravenous injection
Number of subjects: 107
Study 11451725 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + folic acid + vitamin A
Number of subjects: 0
Study 11451725 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + folic acid
Number of subjects: 0
Study 11451725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11451725 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A
Number of subjects: 0
Study 9736235 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 89
Study 9736235 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 89
Study 8017359 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 20
Study 8017359 — intervention group
Group type: COMPARATOR
Intervention: Balloon feedback
Number of subjects: 20
Study 2500139 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 50
Study 2500139 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 50
Study 2500139 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 50
Study 5673964 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim and sulphamethoxazole
Number of subjects: 10
Study 5673964 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 10
Study 29608768 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed intranasal oxycodone ARIR
Number of subjects: 29
Study 28391453 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM) intervention
Number of subjects: 136
Study 28391453 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 136
Study 24760534 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0g/d ginger
Number of subjects: 20
Study 24760534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24760534 — intervention group
Group type: COMPARATOR
Intervention: Ginger and Placebo
Number of subjects: 20
Study 22531614 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (30 Hz, 10 minutes, 3 times a week for 10 weeks)
Number of subjects: 9
Study 22531614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WBV training)
Number of subjects: 9
Study 21307378 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) levels 5.50-5.99%
Number of subjects: 919
Study 21307378 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) levels 6.00-6.49%
Number of subjects: 919
Study 21307378 — intervention group
Group type: COMPARATOR
Intervention: HbA(1c) levels <5.0%
Number of subjects: 919
Study 21307378 — intervention group
Group type: COMPARATOR
Intervention: HbA(1c) levels 5.00-5.49%
Number of subjects: 919
Study 19332184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 18000
Study 19332184 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 18000
Study 19332184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 18000
Study 19332184 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose
Number of subjects: 18000
Study 19332184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Clopidogrel
Number of subjects: 18000
Study 16984555 — intervention group
Group type: EXPERIMENTAL
Intervention: Y chromosome haplogroups
Number of subjects: 68
Study 16984555 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 68
Study 15198118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (weekly for four weeks)
Number of subjects: 46
Study 15198118 — intervention group
Group type: COMPARATOR
Intervention: Conventional day care alone
Number of subjects: 46
Study 11285662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass treatment of all children
Number of subjects: 0
Study 11285662 — intervention group
Group type: COMPARATOR
Intervention: Targeted treatment of clinically active children and their household members
Number of subjects: 0
Study 9253550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypertension with superimposed preeclampsia (black women)
Number of subjects: 282
Study 9253550 — intervention group
Group type: COMPARATOR
Intervention: Chronic hypertension without preeclampsia (white women)
Number of subjects: 282
Study 9253550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypertension without preeclampsia (black women)
Number of subjects: 282
Study 8390420 — intervention group
Group type: EXPERIMENTAL
Intervention: 63 Gy in 5 weeks (45 Gy 'large' field and 18 Gy 'boost')
Number of subjects: 355
Study 8390420 — intervention group
Group type: EXPERIMENTAL
Intervention: 70.2 Gy in 5.5 weeks (50.4 Gy 'large' field and 19.8 Gy 'boost')
Number of subjects: 355
Study 8390420 — intervention group
Group type: EXPERIMENTAL
Intervention: 70.2 Gy in 5 weeks (45 Gy 'large' field and 25.2 Gy 'boost')
Number of subjects: 355
Study 8390420 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 355
Study 3425284 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate weight bearing
Number of subjects: 53
Study 3425284 — intervention group
Group type: COMPARATOR
Intervention: Late weight bearing
Number of subjects: 53
Study 3425284 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation radiographically and by roentgen stereophotogrammetric analysis
Number of subjects: 53
Study 29607846 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 60
Study 29607846 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Health Education
Number of subjects: 60
Study 29607846 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study 27766928 — intervention group
Group type: EXPERIMENTAL
Intervention: Average delta HR/BT with a cut-off ≥ 20
Number of subjects: 124
Study 27766928 — intervention group
Group type: EXPERIMENTAL
Intervention: Assumed delta HR/BT with a cut-off ≥ 5
Number of subjects: 124
Study 24937345 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype P (patients)
Number of subjects: 170
Study 24937345 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype H (hands)
Number of subjects: 170
Study 24937345 — intervention group
Group type: COMPARATOR
Intervention: Provider hands (referent)
Number of subjects: 170
Study 22913430 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20
Study 22913430 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced control condition
Number of subjects: 20
Study 22035502 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in the patient's home
Number of subjects: 0
Study 22035502 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in GP surgeries
Number of subjects: 0
Study 22035502 — intervention group
Group type: COMPARATOR
Intervention: Hospital day unit (control arm)
Number of subjects: 0
Study 22035502 — intervention group
Group type: EXPERIMENTAL
Intervention: All settings (home, GP surgeries, hospital)
Number of subjects: 0
Study 18667247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Treatment (Atorvastatin 80 mg immediately after admission)
Number of subjects: 40
Study 18667247 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (Atorvastatin 20 mg from the day of discharge)
Number of subjects: 40
Study 16556892 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC/IL-2 treatment (10 cycles of IL-2 at 16,400 U/kg and HDC at 0.5 mg, administered subcutaneously twice daily)
Number of subjects: 320
Study 16556892 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 320
Study 12875348 — intervention group
Group type: EXPERIMENTAL
Intervention: A-Cnotren/Pharmaten, Athens, Greece (test preparation)
Number of subjects: 38
Study 14677622 — intervention group
Group type: EXPERIMENTAL
Intervention: gestodene 60 microg/ethinylestradiol 15 microg
Number of subjects: 124
Study 14677622 — intervention group
Group type: COMPARATOR
Intervention: desogestrel 150 microg/ethinylestradiol 20 microg
Number of subjects: 124
Study 8678384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (13.3 mg of zinc from zinc gluconate, one lozenge every 2 hours while awake)
Number of subjects: 100
Study 8678384 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (5% calcium lactate pentahydrate, one lozenge every 2 hours while awake)
Number of subjects: 100
Study 8678384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges
Number of subjects: 100
Study 8678384 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 100
Study 1840138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine co-treatment for 16 days after a 7-day placebo treatment
Number of subjects: 20
Study 1840138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine co-treatment
Number of subjects: 20
Study 1840138 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 7 days
Number of subjects: 20
Study 6121568 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate 6 mg
Number of subjects: 24
Study 6121568 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 6 mg
Number of subjects: 24
Study 6121568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 60 mg
Number of subjects: 24
Study 6121568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 60 micrograms
Number of subjects: 24
Study 30588680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 204
Study 30588680 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 204
Study 30506538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound (IU)
Number of subjects: 169
Study 30506538 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (laparoscopy only)
Number of subjects: 169
Study 26860090 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal plate fixation
Number of subjects: 90
Study 26860090 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and plaster immobilisation
Number of subjects: 90
Study 25153706 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise programme (11 months, 3 times/week for 6 months, 2 times/week for 5 months)
Number of subjects: 159
Study 25153706 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise programme
Number of subjects: 159
Study 25153706 — intervention group
Group type: COMPARATOR
Intervention: Self-management programme only (control)
Number of subjects: 159
Study 22932743 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Spirit intervention plus Optimized Standard Care
Number of subjects: 322
Study 22932743 — intervention group
Group type: COMPARATOR
Intervention: Optimized Standard Care alone
Number of subjects: 322
Study 20709137 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP10)
Number of subjects: 92
Study 20709137 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide (CP16)
Number of subjects: 92
Study 17403074 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG laxative (17 g daily)
Number of subjects: 304
Study 17403074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 17403074 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG treatment weeks
Number of subjects: 304
Study 17403074 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment weeks
Number of subjects: 304
Study 11131817 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with emotionally valenced (threatening) meanings of homographs
Number of subjects: 0
Study 11131817 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with threatening resolutions of ambiguous words
Number of subjects: 0
Study 11131817 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (non-threatening resolutions)
Number of subjects: 0
Study 9065963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 176
Study 9065963 — intervention group
Group type: COMPARATOR
Intervention: Melperone
Number of subjects: 176
Study 8417578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 60
Study 8417578 — intervention group
Group type: COMPARATOR
Intervention: Supportive-expressive therapy (SET)
Number of subjects: 60
Study 3757441 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium diet (1800 mg of calcium/day)
Number of subjects: 8
Study 3757441 — intervention group
Group type: COMPARATOR
Intervention: Low calcium diet (200 mg of calcium/day)
Number of subjects: 8
Study 30593111 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etching (40 s, 35% H3PO4) with glass ionomer cement (Ketac Molar Easymix)
Number of subjects: 100
Study 30593111 — intervention group
Group type: COMPARATOR
Intervention: No acid etching with glass ionomer cement (Ketac Molar Easymix)
Number of subjects: 100
Study 26755409 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-mm in-shoe orthotic heel lift
Number of subjects: 12
Study 25724700 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (3 g/day)
Number of subjects: 50
Study 25724700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23710881 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupuncture bilaterally for 30 minutes, stimulated every 10 minutes to keep de qi sensation
Number of subjects: 0
Study 23710881 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture bilaterally for 30 minutes with no stimulation
Number of subjects: 0
Study 23710881 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 stimulation via active TENS electrodes bilaterally for 30 minutes
Number of subjects: 0
Study 23710881 — intervention group
Group type: COMPARATOR
Intervention: Sham P6 stimulation via inactive TENS electrode bilaterally for 30 minutes
Number of subjects: 0
Study 23710881 — intervention group
Group type: COMPARATOR
Intervention: Usual practice of pharmacological emesis prevention (ondansetron 8 mg)
Number of subjects: 0
Study 20470796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) regimen
Number of subjects: 10
Study 20470796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) regimen
Number of subjects: 10
Study 20470796 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 18241082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design for dose-response trials
Number of subjects: 0
Study 16637749 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat-induced anxiety
Number of subjects: 0
Study 16637749 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of behavioral inhibition
Number of subjects: 0
Study 15030303 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 15030303 — intervention group
Group type: COMPARATOR
Intervention: Dietary measures
Number of subjects: 0
Study 10770216 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (60 microg/kg, sc, twice daily)
Number of subjects: 8
Study 10770216 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (12.5 microg/kg‐day, sc)
Number of subjects: 8
Study 10770216 — intervention group
Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 8
Study 8867568 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2-4 mg once-daily)
Number of subjects: 41
Study 8867568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 1732769 — intervention group
Group type: EXPERIMENTAL
Intervention: High-osmolality contrast agent (Hypaque 76)
Number of subjects: 505
Study 1732769 — intervention group
Group type: COMPARATOR
Intervention: Low-osmolality contrast agent (Omnipaque 350)
Number of subjects: 505
Study 29673832 — intervention group
Group type: EXPERIMENTAL
Intervention: PT using exergames
Number of subjects: 0
Study 29673832 — intervention group
Group type: EXPERIMENTAL
Intervention: PS
Number of subjects: 0
Study 29673832 — intervention group
Group type: EXPERIMENTAL
Intervention: PT using exergames combined with PS
Number of subjects: 0
Study 29673832 — intervention group
Group type: EXPERIMENTAL
Intervention: PT using exergames combined with isoenergetic supplementation
Number of subjects: 0
Study 29673832 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26940805 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 10 mg
Number of subjects: 207
Study 26940805 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg
Number of subjects: 207
Study 26940805 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg (nonsmokers)
Number of subjects: 207
Study 26940805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 24290843 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg Vi-CRM197
Number of subjects: 320
Study 24290843 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-CRM197
Number of subjects: 320